Tamyres Mingorance Carvalho

Dr. Tamyres Mingorance Carvalho

Federal University of Paraná, Curitiba, Paraná, Brazil
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JBJéssica Fernanda Barazetti
Jéssica Fernanda Barazetti
TJTayana Shultz Jucoski
Tayana Shultz Jucoski
TCTamyres Mingorance Carvalho
Tamyres Mingorance Carvalho
RVRafaela Nasser Veiga
Rafaela Nasser Veiga
AKAna Flávia Kohler
Ana Flávia Kohler
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality among women. Two thirds of patients are classified as hormone receptor positive, based on expression of estrogen receptor alpha (ERα), the main driver of breast cancer cell proliferation, and/or progesterone receptor, which is regulated by ERα. Despite presenting the best prognosis, these tumors can recur when patients acquire resistance to treatment by aromatase inhibitors or antiestrogen such as tamoxifen (Tam). The mechanisms that are involved in Tam resistance are complex and involve multiple signaling pathways. Recently, roles for microRNAs and lncRNAs in controlling ER expression and/or tamoxifen action have been described, but the underlying mechanisms are still little explored. In this review, we will discuss the current state of knowledge on the roles of microRNAs and lncRNAs in the main mechanisms of tamoxifen resistance in hormone receptor positive breast cancer. In the future, this knowledge can be used to identify patients at a greater risk of relapse due to the expression patterns of ncRNAs that impact response to Tam, in order to guide their treatment more efficiently and possibly to design therapeutic strategies to bypass mechanisms of resistance.

10 November 2022 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
CMCristiane Sato Mara Muller
Cristiane Sato Mara Muller
IGIgor Samesima Giner
Igor Samesima Giner
EZErika Zambalde
Erika Zambalde
TCTamyres Mingorance Carvalho
Tamyres Mingorance Carvalho
EREnilze Maria de Souza Fonseca Ribeiro
Enilze Maria de Souza Fonseca Ribeiro
Daniela GradiaDaniela Gradia
Daniela Gradia
Introduction: Long non-coding RNAs (LncRNA) represent a heterogeneous family of RNAs that have emerged as regulators of various biological processes through their association with proteins in ribonucleoproteins complexes. The dynamic of these interactions can affect cell metabolism, including cancer development. Annually, breast cancer causes thousands of deaths worldwide, and searching for new biomarkers is pivotal for better diagnosis and treatment. Methods: Based on in silico prediction analysis, we focus on LncRNAs that have binding sites for PUMILIO, an RBP family involved in post-transcriptional regulation and associated with cancer progression. We compared the expression levels of these LncRNAs in breast cancer and non-tumor samples from the TCGA database. We analyzed the impact of overall and disease-free survival associated with the expression of the LncRNAs and co-expressed genes and targets of PUMILIO proteins. Results: Our results found NORAD as the most relevant LncRNA with a PUMILIO binding site in breast cancer, differently expressed between Luminal A and Basal subtypes. Additionally, NORAD was co-expressed in a Basal-like subtype (0.55) with the RALGAPB gene, a target gene of PUMILIO related to chromosome stability during cell division. Conclusion: These data suggest that this molecular axis may provide insights for developing novel therapeutic strategies for breast cancer.